Kingfisher Biotech's portfolio of VEGF-A recombinant proteins includes, bovine, canine, equine, feline, mouse, ovine, rabbit , rat, swine, and zebrafish VEGF-A.
Vascular endothelial growth factor (VEGF) proteins stimulate vasculogenesis and angiogenesis. They are part of the system that restores the oxygen supply to tissues when blood circulation is inadequate. The normal function of VEGF proteins is to create new blood vessels during embryonic development, new blood vessels after injury, muscle following exercise, and new vessels (collateral circulation) to bypass blocked vessels. The VEGF family has six members, including VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and Placental Growth Factor (PGF). Activity of VEGF-A, as its name implies, has been studied mostly on cells of the vascular endothelium, although it does have effects on a number of other cell types (e.g., stimulation monocyte/macrophage migration, neurons, cancer cells, kidney epithelial cells). In vitro, VEGF-A has been shown to stimulate endothelial cell mitogenesis and cell migration. VEGF-A is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor (VPF).
A recent bioassay of our bovine, canine, and mouse VEGF-A based on the proliferation of HUVECs demonstrated that all three proteins are highly active on the human cell line.
Showing posts with label Rat. Show all posts
Showing posts with label Rat. Show all posts
Friday, February 19, 2016
Wednesday, July 8, 2015
New Products - July 2015
Kingfisher Biotech, Inc. is committed to accelerating basic veterinary research and human disease research done in animal models by developing and commercializing research reagents specific for a variety of species, including bovine, canine, caprine, chicken, dolphin, equine, feline, guinea pig, hamster, human, mouse, ovine, rabbit, rat, swine, and turkey. We have just started adding cynomolgus monkey and zebrafish products. Currently, we offer over 1200 recombinant proteins, polyclonal antibodies, monoclonal antibodies and ELISA kits for animal health and animal model research. Our products are primarily cytokines, chemokines, interferons, and growth factors. Our product development queue is filled mainly by customer requests. If there is a product that you are looking for and can't find, please send us an email.
Below is a list of our newest recombinant proteins with links to website with additional information on each product.
Below is a list of our newest recombinant proteins with links to website with additional information on each product.
Thursday, May 28, 2015
New Products - May 2015
Kingfisher Biotech, Inc. is committed to accelerating basic veterinary research and human disease research done in animal models by developing and commercializing research reagents specific for a variety of species, including bovine, canine, caprine, chicken, dolphin, equine, feline, guinea pig, hamster, human, mouse, ovine, rabbit, rat, swine, and turkey. We have just started adding cynomolgus monkey and zebrafish products. Currently, we offer over 1200 recombinant proteins, polyclonal antibodies, monoclonal antibodies and ELISA kits for animal health and animal model research. Our products are primarily cytokines, chemokines, interferons, and growth factors. Our product development queue is filled mainly by customer requests. If there is a product that you are looking for and can't find, please send us an email.
Below is a list of our newest recombinant proteins and specialty products with links to website with additional information on each product.
Below is a list of our newest recombinant proteins and specialty products with links to website with additional information on each product.
- Zebrafish IL-10 (CSIF)
- Cynomolgus Monkey IL-6
- Cynomolgus TNF alpha
- Swine Leukemia Inhibitory Factor (LIF)
- Rabbit CCL3 (MIP-1 alpha)
- Canine Leukemia Inhibitory Factor (LIF)
- Rabbit Leukemia Inhibitory Factor (LIF)
- Bovine Dendritic Cell Growth Cocktail
- Bovine Annexin V Fluorescein
- Canine Annexin V Fluorescein
- Chicken Annexin V Fluorescein
- Equine Annexin V Fluorescein
- Swine Annexin V Fluorescein
Thursday, April 16, 2015
New Recombinant Proteins - April 2015
Kingfisher Biotech, Inc. is committed to accelerating basic veterinary research and human disease research done in animal models by developing and commercializing research reagents specific for a variety of species, including bovine, canine, caprine, chicken, dolphin, equine, feline, guinea pig, hamster, human, mouse, ovine, rabbit, rat, swine, and turkey. We will continue to add species as our customer request specific reagents for their research. Currently, we offer over 1200 recombinant proteins, polyclonal antibodies, monoclonal antibodies and ELISA kits for animal health and animal model research. Our products are primarily cytokines, chemokines, interferons, and growth factors. Our product development queue is filled mainly by customer requests. If there is a product that you are looking for and can't find, please send us an email.
Below is a list of our newest proteins with links to website with additional information on each protein.
Below is a list of our newest proteins with links to website with additional information on each protein.
Monday, November 14, 2011
TNF alpha Homology Across Species
TNF alpha is able to induce fever, apoptotic cell death, sepsis (through IL-1 & IL-6 production), cachexia, and inflammation, as well as to inhibit tumorigenesis and viral replication. Because of the broad role of TNF alpha, dysregulation has been implicated in a variety of diseases.
Labels:
Animal Model,
canine,
Equine,
Guinea Pig,
Inflammation,
Mouse,
ovine,
Rabbit,
Rat,
swine,
TNF alpha
Sunday, October 30, 2011
Rabbit as an Animal Model for Osteoarthritis Research
In humans, osteoarthritis (OA) develops either idiopathically and progresses slowly with age or secondarily to trauma and progresses rapidly. OA is associated with changes to all joint tissues including articular cartilage, subchondral bone, synovium, ligaments, and muscles. Clinically, OA-mediated joint damage results in reduced mobility, pain, and fatigue. While several disease modifying OA drugs are in various stages of development, none have yet been approved for human use. Concurrent research in humans as well as experimental animal models will be important for the discovery of new therapeutics. Since no single experimental model provides the complete picture of OA in humans, a variety of animals have served to advance OA research including mouse, rat, guinea pig, rabbit, dog, and horse. [1,2]
A broad range of rabbit OA models have been used extensively and continue to offer specific advantages over other models for OA research. The gross anatomy of the rabbit knee is very similar to that of humans. Moreover, the rabbit knee joint is large enough to enable the harvest of adequate volumes of tissue for histopathological analysis, a major limitation of smaller animal models. In adult humans, the growth plates in the long bones no longer retain the capacity for growth and are termed “closed.” This is also the case in skeletally-mature rabbits. By contrast, mouse and rat growth plates do not normally close completely and longitudinal bone growth can be reinitiated even in mature animals. This is a complicating issue for data interpretation and limits the translatability of research performed using mice and rats. [2]
Most often, skeletally-mature, male, NZW rabbits are used for OA studies in an attempt to ensure bone growth plate closure, reduce hormone fluctuation, and control for potential inter-strain variability. OA does not occur spontaneously in rabbits, but can be induced via surgical intervention (i.e., meniscectomy or anterior cruciate ligament transection [ACLT]), mechanical manipulation (i.e., impact or immobilization), or chemical application (i.e., IL-1β, collagenase, etc.). The majority of rabbit OA studies employ the ACLT model as it offers several advantages. ACLT-modified rabbits very quickly develop a wide variety of cartilage lesions post-surgically, which closely approximate many aspects of human OA. The histopathology of the rabbit ACLT model has been studied extensively and a standardized nomenclature and scoring scheme for evaluating and comparing alterations in joint structures, including changes in cartilage, synovium and bone, have been proposed. Further, a sizeable body of data derived from this model has already been amassed describing OA pathogenesis including imaging studies and effects of various potential pharmacological applications. [2]
References
1. Poole, R. et al. (2010) Recommendations for the use of preclinical models in the study and treatment of osteoarthritis. Osteoarthritis Cartilage 18(Suppl. 3):S10-S16.
2. Laverty, S. et al. (2010) The OARSI histopathology initiative – recommendations for histological assessments of osteoarthritis in the rabbit. Osteoarthritis Cartilage 18(Suppl. 3):S53-S65.
A broad range of rabbit OA models have been used extensively and continue to offer specific advantages over other models for OA research. The gross anatomy of the rabbit knee is very similar to that of humans. Moreover, the rabbit knee joint is large enough to enable the harvest of adequate volumes of tissue for histopathological analysis, a major limitation of smaller animal models. In adult humans, the growth plates in the long bones no longer retain the capacity for growth and are termed “closed.” This is also the case in skeletally-mature rabbits. By contrast, mouse and rat growth plates do not normally close completely and longitudinal bone growth can be reinitiated even in mature animals. This is a complicating issue for data interpretation and limits the translatability of research performed using mice and rats. [2]
Most often, skeletally-mature, male, NZW rabbits are used for OA studies in an attempt to ensure bone growth plate closure, reduce hormone fluctuation, and control for potential inter-strain variability. OA does not occur spontaneously in rabbits, but can be induced via surgical intervention (i.e., meniscectomy or anterior cruciate ligament transection [ACLT]), mechanical manipulation (i.e., impact or immobilization), or chemical application (i.e., IL-1β, collagenase, etc.). The majority of rabbit OA studies employ the ACLT model as it offers several advantages. ACLT-modified rabbits very quickly develop a wide variety of cartilage lesions post-surgically, which closely approximate many aspects of human OA. The histopathology of the rabbit ACLT model has been studied extensively and a standardized nomenclature and scoring scheme for evaluating and comparing alterations in joint structures, including changes in cartilage, synovium and bone, have been proposed. Further, a sizeable body of data derived from this model has already been amassed describing OA pathogenesis including imaging studies and effects of various potential pharmacological applications. [2]
References
1. Poole, R. et al. (2010) Recommendations for the use of preclinical models in the study and treatment of osteoarthritis. Osteoarthritis Cartilage 18(Suppl. 3):S10-S16.
2. Laverty, S. et al. (2010) The OARSI histopathology initiative – recommendations for histological assessments of osteoarthritis in the rabbit. Osteoarthritis Cartilage 18(Suppl. 3):S53-S65.
Labels:
Animal Model,
canine,
Equine,
Guinea Pig,
Mouse,
Osteoarthritis,
Rabbit,
Rat
Subscribe to:
Posts (Atom)

